Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir

AIDS Research and Human Retroviruses

Volumn 30, Issue 4, 2014, Pages 363-369

  Jablonowska, Elzbieta ^a   Wójcik, Kamila ^a   Piekarska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; CREATININE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FATTY ACID BINDING PROTEIN; KIDNEY INJURY MOLECULE 1; LIVER TYPE FATTY ACID BINDING PROTEIN; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TUBULE DAMAGE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN URINE LEVEL;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; FATTY ACID-BINDING PROTEINS; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; ORGANOPHOSPHONATES; RECEPTORS, VIRUS;

EID: 84898733748     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0070     Document Type: Article

References (32)

1. Mocroft A, Reiss P, Gasiorowski J, et al.: Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010;55:262-270.
2. UNAIDS. Report on the Global AIDS Epidemic: www .unaids.org/en/media/ unaids/contentassets/documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global- Report-2012-with-Annexes-en.pdf 2012.
3. Emery S, Neuhaus JA, Phillips AN, et al.: Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008;197:1133-1144. (Pubitemid 351590049)
4. Kalayjian RC, Lau B, Mechekano RN, et al.: Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012;26:1907-1915.
5. Peters PJ, Moore DM, Mermin J, et al.: Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 2008;74:925-929.
6. Daugas E, Rougier JP, and Hill G: HAART-related nephropathies in HIV-infected patients. Kidney Int 2005;67: 393-403. (Pubitemid 40139831)
7. Roling J, Schmid H, Fischereder M, Draenert R, and Goebel FD: HIV-Associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006;42:1488-1495.
8. Pelsers MM: Fatty acid-binding protein as marker for renal injury. Scand J Clin Lab Invest Suppl 2008;241:73-77. (Pubitemid 351883662)
9. Yamamoto T, Noiri E, Ono Y, et al.: Renal L-type fatty acidbinding protein in acute ischemic injury. J Am Soc Nephrol 2007;18:2894-2902. (Pubitemid 350058396)
10. Kamijo A, Sugaya T, Hikawa A, et al.: Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial. J Lab Clin Med 2005;145:125-133. (Pubitemid 40432361)
11. Huo W, Zhang K, Nie Z, Li Q, and Jin F: Kidney injury molecule-1 (KIM-1): A novel kidney-specific injury molecule playing potential double-edged functions in kidney injury. Transplant Rev 2010;24:143-146.
12. Zhang Z, Humphreys BD, and Bonventre JV: Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J Am Soc Nephrol 2007;18:2704-2714. (Pubitemid 47531197)
13. Bonventre JV: Kidney injury molecule-1 (KIM-1): A urinary biomarker and much more. Nephrol Dial Transplant 2009; 24:3265-3268.
14. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, and Stegeman CA: Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007;212:209-217. (Pubitemid 46852099)
15. EACS: European guidelines for treatment of HIV infected adults in Europe (Version 6.1): www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ EacsGuidelines-v6.1-2edition.pdf 2012.
16. Zasady Opieki nad Osobami Zaka-zonymi HIV (Horbana A, Podlasin R, Cholewiń ska G, Wierciń ska-Drapa1o A, Knysz B, Inglot M, Szymczak A, eds.). Polish AIDS Society, Warszawa-Wroc1aw, 2013, pp. 1-432.
17. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo .nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf 2013.
18. Thompson MA, Aberg JA, Hoy JF, et al.: Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
19. Mocroft A, Kirk O, Reiss P, et al.: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667-1678.
20. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, and Nitta K: Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Nephrol Dial Transplant 2011;26:3224-3229.
21. Hall AM, Edwards SG, Lapsley M, et al.: Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: A cross-sectional analysis. Am J Kidney Dis 2009;54:1034-1042.
22. Kinai E and Hanabusa H: Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS 2005;19:2031-2033. (Pubitemid 41669029)
23. Kasuno K, Ono T, Matsumori A, et al.: Hepatitis C virusassociated tubulointerstitial injury. Am J Kidney Dis 2003; 41:767-775.
24. Sansonno D and Dammacco F: Hepatitis C virus, cryoglobulinaemia, and vasculitis: Immune complex relations. Lancet Infect Dis 2005;5:227-236. (Pubitemid 40410068)
25. Rodriguez-Inigo E, Casqueiro M, Bartolome J, et al.: Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases. J Viral Hepat 2000;7:23-29. (Pubitemid 30139848)
26. Sansonno D, Lauletta G, Montrone M, Grandaliano G, Schena FP, and Dammacco F: Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol 2005;140:498-506. (Pubitemid 40813960)
27. Peters L, Grint D, Lundgren JD, et al.: Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012;26:1917-1926.
28. Rodriguez-Novoa S, Labarga P, Soriano V, et al.: Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: A pharmacogenetic study. Clin Infect Dis 2009;48:e108-e116.
29. Rodriguez-Novoa S, Labarga P, D'avolio A, et al.: Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 2010;24:1064-1066.
30. Kiser JJ, Carten ML, Aquilante CL, et al.: The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIVinfected patients. Clin Pharmacol Ther 2008;83:265-272.
31. Fux CA, Simcock M, Wolbers M, et al.: Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007;12: 1165-1173.
32. Goicoechea M, Liu S, Best B, et al.: Greater tenofovir-Associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-108. (Pubitemid 351263473)